Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04741698
Other study ID # DDD# 604829
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 27, 2021
Est. completion date July 1, 2022

Study information

Verified date July 2022
Source Christiana Care Health Services
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Induction of labor is one of the most common procedures performed on labor and delivery. In the United States, more than 20 percent of pregnant women undergo an induction of labor [1]. There is data from small, randomized studies that demonstrates the effectiveness of propranolol, a non-selective beta-blocker, for labor augmentation. This literature suggests a decrease in the amount of time to delivery and a possible reduction in cesarean section rates when propranolol is used in conjunction with oxytocin for induction of labor compared to oxytocin alone [2-8]. Alpha- and beta-adrenergic receptors have been identified in the human myometrium. Propranolol has been shown in studies to enhance uterine contractions and may be a useful tool in this population of women. Therefore, the purpose of this study is to assess whether the administration of propranolol at time of labor dystocia reduces time to delivery.


Description:

All cervical ripening will be performed in the labor and delivery unit; continuous fetal heart rate and uterine activity will be monitored in all patients. Cervical dilation is assigned by admitting physicians. Sonography will be performed to document fetal presentation. At the time of prolonged labor, patients meeting inclusion criteria and no exclusion criteria will be consented. There will be no monetary incentives for participation. Patients will be randomized to either Propranolol 2mg of IV or expectant management at the time of induction. Maternal vitals will be collected per standard labor management. Episodes of uterine activity that are deemed excessive by the physician will be treated with a standard combination of maneuvers that included a change in maternal position, oxygen administration, and terbutaline 250 µg subcutaneously. Persistent abnormal fetal heart rate patterns resulted in intervention by removing the patient from the study. Urgent cesarean delivery is defined as a cesarean delivery performed during the ripening process for abnormal fetal heart rate that did not respond to standard maneuvers.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date July 1, 2022
Est. primary completion date June 11, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - =18 years of age - full term (=37 weeks) gestations determined by routine obstetrical guidelines - singleton gestation in cephalic presentation - Intact membranes - Bishop score of =6 and cervical dilation =2cm Exclusion Criteria: - Preterm gestation - Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate - multiparous women - Any cardiac condition for which ß blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block) - Known hypersensitivity to propranolol - Maternal bradycardia (HR <60bpm) - Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control - Systolic blood pressure <90 mmHg, or diastolic blood pressure <50 mmHg - Receiving other beta blocker - Moderate or severe asthma: as this is a contraindication to beta blocker use - Any contraindication to a vaginal delivery - fetal demise - Multifetal gestation - major fetal anomaly - prior uterine surgery, previous cesarean section - women with HIV, hepatitis C, hepatitis B, and women with medical conditions requiring an assisted second stage - Additional exclusion criteria were as follows: category 3 fetal heart rate tracing, hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia, growth restriction <10th percentile (based on Hadlock growth curves) with reversal of flow in umbilical artery Doppler studies, and growth restriction <5th percentile with elevated, absent, or reversal of flow in umbilical artery Doppler studies.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propranolol
Propranolol 2mg IV

Locations

Country Name City State
United States Christiana Care Newark Delaware

Sponsors (1)

Lead Sponsor Collaborator
Christiana Care Health Services

Country where clinical trial is conducted

United States, 

References & Publications (7)

Kashanian M, Fekrat M, Zarrin Z, Ansari NS. A comparison between the effect of oxytocin only and oxytocin plus propranolol on the labor (a double blind randomized trial). J Obstet Gynaecol Res. 2008 Jun;34(3):354-8. doi: 10.1111/j.1447-0756.2008.00790.x. — View Citation

Meidahl Petersen K, Jimenez-Solem E, Andersen JT, Petersen M, Brødbæk K, Køber L, Torp-Pedersen C, Poulsen HE. ß-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open. 2012 Jul 19;2(4). pii: e001185. doi: 10.1136/bmjopen-2012-001185. Print 2012. — View Citation

Moghadam AD, Jaafarpour M, Khani A. Comparison effect of oral propranolol and oxytocin versus oxytocin only on induction of labour in nulliparous women (a double blind randomized trial). J Clin Diagn Res. 2013 Nov;7(11):2567-9. doi: 10.7860/JCDR/2013/5704.3613. Epub 2013 Nov 10. Erratum in: J Clin Diagn Res. 2015 Aug;9(8):ZZ01. — View Citation

Palomäki O, Uotila J, Tammela O, Kaila T, Lavapuro M, Huhtala H, Tuimala R. A double blind, randomized trial on augmentation of labour with a combination of intravenous propranolol and oxytocin versus oxytocin only. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1;125(1):44-9. Epub 2005 Jul 26. — View Citation

Pergialiotis V, Frountzas M, Prodromidou A, Prapa S, Perrea DN, Vlachos GD. Propranolol and oxytocin versus oxytocin alone for induction and augmentation of labor: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2016 Apr;293(4):721-9. doi: 10.1007/s00404-015-3991-8. Epub 2015 Dec 22. Review. — View Citation

Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15;135(4):485-9. — View Citation

Sanchez-Ramos L, Quillen MJ, Kaunitz AM. Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor. Obstet Gynecol. 1996 Oct;88(4 Pt 1):517-20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary time to delivery The primary outcome is time to delivery (hours) defined as time from initiation of induction method to delivery time, regardless of mode of delivery. Number of hours from induction to delivery of neonate; up to 72 hours.
Secondary cesarean delivery rate rate of cesarean delivery At time of delivery
Secondary maternal length of stay from time of admission to discharge From time of admission to time of hospital discharge; an average of two days
Secondary Maternal Bradycardia event bradycardia alert during labor at time of delivery
Secondary Chorioamnionitis defined by the presence of maternal fever =100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness At time of delivery
Secondary neonatal admission to ICU NICU admission At time of delivery
Secondary Severe respiratory distress syndrome defined as intubation and mechanical ventilation for a minimum of 12 hours at time of delivery
Secondary neonatal sepsis Culture proven-presumed neonatal sepsis at time of delivery
Secondary Neonatal blood transfusion Neonatal blood transfusion From time of delivery to time of hospital discharge; up to 6 weeks
Secondary Hypoxic ischemic encephalopathy neonatal HIE through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05791630 - The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) N/A
Recruiting NCT06268431 - Oxytocin Rest to Reduce Cesarean Delivery N/A
Not yet recruiting NCT05881629 - Early Diagnosis and Intervention for Fetal Malposition in Active Labor and Its Impact on Mode of Delivery N/A